Thanks, Logan, but it wasn't a good call on my part because JMcD isn't a pharmacologist. As you correctly state, he's a pharmacist. Although it won't be long before he'll be able to qualify as a pharmacologist based on the wealth of experience he'll garner here at PTX.
What are my thoughts on the potential addressable market return for treating 10% of all RAS pathway mutations in bowel cancer? Well, without having really thought about the numbers and potential there, I can only but consult AI first. Lets see what Grok presents:
I can see why you chose Bowel Cancer to critique the addressable market for PTX-100. Holy crap (pardon the pun), its a humungous addressable market. So in reply to your question, my thoughts on a 20% share of the above range is: "That's yuge! USD 140 million to USD 200 million = AUD 214 million to AUD 305 million. 'From Little Things, Big Things Grow'... the potential is enormous if our Ph2 trial succeeds!"
Add to My Watchlist
What is My Watchlist?
